The present invention consists of compounds that can be represented by general formula (1) or a pharmacologically permitted salt thereof (1) (In the formula, R1, R2, R3, and R4 are as defined in the specification.) for use in therapy for parathyroid hormone 1 (PTH) receptor mediated disorders.